How Do Pharmaceutical Teams Verify an Adverse Drug Reaction Claim in the Medical Records?

A report arrives describing hepatic injury in a patient who took the product for six weeks. Attached to it are 900 pages from four providers, a discharge summary, two sets of labs, and a pharmacy printout.

Somewhere in that stack is the answer to a narrow question: what do the records actually document about this exposure and this event?

Not whether the drug caused it. That determination sits with the safety physician and the applicable assessment framework. But the assessment is only as good as the record underneath it, and the record arrives disorganized, partial, and full of entries that look like evidence without being it.

This is where medical record review does its work in pharmacovigilance and product liability files: establishing what the documentation supports before anyone applies judgment to it.

What the Records Can Establish

A verification review answers a short list of factual questions and refuses the rest.

Exposure as Documented

Start with what the chart says about the product itself. The prescription date, the dose, the formulation, the duration, refills, and any documented change to the regimen. A pharmacy record and a treating note can disagree about all of these, and the review should show both rather than pick one.

Exposure is the foundation. An event that predates the first documented dose changes the file entirely, and that comparison is impossible until the exposure dates are pinned to sources.

Timing of the Event

Two dates matter and they are not the same. The date the patient reported symptoms beginning, and the date the records first document them. A patient may report onset in March while the first clinical entry appears in May.

Neither is more true than the other. A review that collapses them into one date has destroyed information the assessor needed.

What Else Was in the Chart

Concomitant medications, prior conditions, recent procedures, alternative documented causes, relevant labs before exposure. These are not distractions from the claim. They are the context any structured assessment will ask for, and they should arrive with the file rather than after the first round of questions.

Why Verification Starts With Sequence

The whole question is sequence, and sequence is the one thing a stack of PDFs destroys.

Before the First Dose

Build the pre-exposure picture first. What conditions were documented, what medications were already running, what the relevant baseline labs showed, what the patient was being treated for.

Without that baseline, an abnormal liver panel three weeks into treatment looks like a signal. With it, the same panel might be the fourth in a series that started abnormal.

After the First Dose

Then the post-exposure course, read against that baseline. When symptoms appear in the record, what the treating provider did, whether the drug was stopped, whether symptoms changed after it was stopped, and whether it was ever restarted.

That last sequence, the stop and any restart, is often the most informative content in the file. It is almost never labeled as such. It sits inside a routine follow-up note as a sentence about discontinuing a medication. The same reading discipline drives medical record red flags in mass tort claimant screening, where what the file supports is decided by sequence rather than volume.

Where These Files Go Wrong

Five failures recur in adverse event record sets.

Reported Onset Treated as Documented Onset

The report form says symptoms began on a date. The review repeats that date as though the chart established it. Every downstream reader now believes the record documents something it does not. Label the source of every date: patient-reported, provider-documented, or inferred from a lab result.

Concomitant Medications Left Out

A review focused on the suspect product alone produces a file that cannot support any structured assessment. Other drugs the patient was taking, including over-the-counter products and supplements where the chart records them, belong in the timeline.

Dechallenge and Rechallenge Missed

Because these are rarely labeled, a reviewer scanning for the event itself will read straight past the note that documents the drug being stopped, or restarted. Both deserve their own line in the review with the date and the source page.

Prior Conditions Without Sources

"History of liver disease" appearing in a problem list is not a documented prior condition. It is a line someone typed, possibly years ago, carried forward ever since. Trace it to the earliest note that records it, or mark it as unsourced.

Causality Written Into the Summary

A review that says "unlikely related to study drug" or "consistent with drug-induced injury" has crossed a line it cannot come back from. Whoever reads that summary next is now reading an opinion formed by someone with no standing to form it, and the assessment that follows is contaminated.

What a Verification-Ready Review Delivers

Six things, each findable in under a minute.

The Six Elements

1. An exposure record showing drug, dose, formulation, start date, duration and any documented change, with sources
2. Two onset dates, reported and documented, labeled as such
3. A concomitant medication list covering the exposure window
4. Dechallenge and rechallenge entries called out separately with dates and pages
5. Relevant labs and diagnostics before, during and after exposure, in sequence
6. Prior conditions and alternative documented causes, each traced to its earliest source

Questions to Ask Before You Rely on a Review

• Which exposure dates come from the pharmacy record and which from a treating note, and do they agree?
• Is the reported onset distinguished from the first documented entry?
• Does the concomitant medication list cover the full exposure window?
• Are dechallenge and rechallenge identified, or buried in follow-up notes?
• Is every prior condition traced to the note that first documents it?
• Does the summary anywhere characterize the event as related or unrelated?
• Who performed the human verification after any AI-assisted extraction?

Where the Review Stops

This boundary is not a formality in pharmacovigilance work. It is the thing that makes the review usable.

Medical record review identifies, dates, organizes, cross-references and flags what the documents say. It does not assess causality. It does not apply an assessment framework, score relatedness, judge expectedness, determine seriousness, or decide what is reportable and to whom.

Those are determinations for the qualified safety physician, the medical monitor, and the sponsor's own procedures under the applicable regulations. A review that reaches into that territory exceeds its remit, and worse, it makes the record less useful, because a summary carrying a conclusion cannot serve as neutral input to the assessment that produces one.

The same discipline applies to the AI layer. Extraction and indexing at this volume benefit from it, and auditing AI-assisted medical data analysis is how the output stays trustworthy. A trained medical reviewer verifies context, dates and source accuracy before anything reaches an assessor.

The Bottom Line

Verifying an adverse drug reaction claim in the medical records is not a search for the answer. It is the work of making the documented facts visible enough that a qualified professional can reach one.

Exposure with sources. Two onset dates, kept apart. Concomitant therapy across the window. The stop and any restart, pulled out of the notes that hide them. Prior conditions traced to their first mention rather than their hundredth.

Do that, and the assessment rests on a record that holds up. Let a conclusion slip into the summary, and it rests on someone's guess wearing a citation. The difference matters here more than almost anywhere else in medical-legal work, because the reader downstream is making a safety determination. Treating every source type the same way is how that record quietly stops being reliable, and the wider medical record review library works through the rest.

Source Credit: Turnaround and volume figures are LezDo TechMed published service benchmarks and company figures.